272 460

Cited 4 times in

Systemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment

DC Field Value Language
dc.contributor.author김종찬-
dc.contributor.author박지수-
dc.contributor.author장원식-
dc.contributor.author함원식-
dc.date.accessioned2022-03-11T05:58:31Z-
dc.date.available2022-03-11T05:58:31Z-
dc.date.issued2022-01-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/187888-
dc.description.abstractImmune checkpoint inhibitors and tyrosine kinase inhibitors are the first-line treatment for metastatic renal cell carcinoma (mRCC), but their benefits are limited to specific patient subsets. Here, we aimed to evaluate the therapeutic efficacy of JX-594 (pexastimogene devacirepvec, Pexa-vec) monotherapy by systemic injection in comparison with sunitinib monotherapy in metastatic orthotopic RCC murine models. Two highly metastatic orthotopic RCC models were developed to compare the treatment efficacy in the International Metastatic RCC Database Consortium favorable-risk and intermediate- or poor-risk groups. JX-594 was systemically injected through the peritoneum, whereas sunitinib was orally administered. Post-treatment, tumor microenvironment (TME) remodeling was determined using immunofluorescence analysis. Systemic JX-594 monotherapy injection demonstrated therapeutic benefit in both early- and advanced-stage mRCC models. Sunitinib monotherapy significantly reduced the primary tumor burden and number of lung metastases in the early-stage, but not in the advanced-stage mRCC model. Systemic JX-594 delivery remodeled the primary TME and lung metastatic sites by increasing tumor-infiltrating CD4/8+ T cells and dendritic cells. Systemic JX-594 monotherapy demonstrated significantly better therapeutic outcomes compared with sunitinib monotherapy in both early- and advanced-stage mRCCs by converting cold tumors into hot tumors. Sunitinib monotherapy effectively suppressed primary tumor growth and lung metastasis in early-stage mRCC.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherMDPI AG-
dc.relation.isPartOfBIOMEDICINES-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleSystemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Urology (비뇨의학교실)-
dc.contributor.googleauthorJee Soo Park-
dc.contributor.googleauthorMyung Eun Lee-
dc.contributor.googleauthorWon Sik Jang-
dc.contributor.googleauthorJongchan Kim-
dc.contributor.googleauthorSe Mi Park-
dc.contributor.googleauthorKeunhee Oh-
dc.contributor.googleauthorNamhee Lee-
dc.contributor.googleauthorWon Sik Ham-
dc.identifier.doi10.3390/biomedicines10010173-
dc.contributor.localIdA04541-
dc.contributor.localIdA05336-
dc.contributor.localIdA05268-
dc.contributor.localIdA04337-
dc.relation.journalcodeJ03914-
dc.identifier.eissn2227-9059-
dc.identifier.pmid35052851-
dc.subject.keywordimmunotherapy-
dc.subject.keywordoncolytic vaccinia virus-
dc.subject.keywordpexastimogene devacirepvec (pexa-vec)-
dc.subject.keywordrenal cell carcinoma-
dc.subject.keywordsunitinib-
dc.contributor.alternativeNameKim, Jong Chan-
dc.contributor.affiliatedAuthor김종찬-
dc.contributor.affiliatedAuthor박지수-
dc.contributor.affiliatedAuthor장원식-
dc.contributor.affiliatedAuthor함원식-
dc.citation.volume10-
dc.citation.number1-
dc.citation.startPage173-
dc.identifier.bibliographicCitationBIOMEDICINES, Vol.10(1) : 173, 2022-01-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.